Opening the Window of Opportunity: Strategies for Successful Treatment and Management of Patients with Crohn's DiseasePremiere Date: Tuesday, May 25, 2021
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, May 25, 2022
Note: Credit Is No Longer Available
|David T. Rubin, MD (Moderator)
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
|Anita Afzali, MD, MPH, FACG, AGAF
Associate Professor of Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, OSU Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
|Millie D. Long, MD, MPH
Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Crohn's disease (CD) is characterized by transmural inflammation and systemic, extraintestinal manifestations that can cause a range of clinical presentations. Traditional management of CD is based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms, which does not improve long-term outcomes in CD and also increases risk for bowel damage. On the other hand, incorporating elements of prognosis into treatment decisions and implementing treat-to-target and tight-control treatment strategies using appropriate therapies can significantly improve patient outcomes.
This CME Outfitters webcast will feature expert faculty leading a case-based discussion that focuses on applying prognosis to treatment decisions, choosing optimal treatment strategies, differentiating targeted therapies, and engaging patients with CD in shared decision-making.
At the end of this CE activity, participants should be able to:
- Differentiate biologic therapies in CD based on their mechanisms of action (MOAs), efficacy, safety, and ability to induce rapid and durable treatment response.
- Incorporate elements of prognosis into treatment decisions in CD based on clinical research data and guideline recommendations.
- Implement strategies to engage all patients with CD in shared decision-making with the goal of increasing patient satisfaction, clinical outcomes, and treatment adherence.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Differentiate biologic therapies in CD based on their MOAs, efficacy, safety, and ability to induce rapid and durable treatment response.
- Explain elements of prognosis for treatment decisions in CD based on clinical research data and guideline recommendations.
- Describe strategies to engage all patients with CD in shared decision-making with the goal of increasing patient satisfaction, clinical outcomes, and treatment adherence.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
This program is not affiliated with Digestive Disease Week®
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Bellatrix Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CDx Diagnostics; Celgene Corporation/Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; Ichnos Sciences SA; InDex Pharmaceuticals; Iterative Scopes, Inc.; Janssen Pharmaceuticals, Inc.; Materia Prima; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is on the board of trustees for American College of Gastroenterology; Co-Founder, CFO of Cornerstones Health, Inc. (non-profit) and Co-Founder of GoDuRn, LLC.
Dr. Afzali reports that she serves on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Long reports that she receives grants and research support from Pfizer Inc. and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).